Actavis acquisition gives Teva new OTC options

16 September 2016 - Deborah Wilkes

Archived

Israeli generics giant Teva is developing an independent OTC strategy following the recent acquisition of Allergan's Actavis generics business, including the international OTC unit. The acquired OTC brands, including Sudocrem and Troxevasin, will not be put into PGT Healthcare, the international OTC joint venture between Procter & Gamble and Teva.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: